Brief Webinar: Changes in Federal Regulation Regarding Medical Providers Prescribing Buprenorphine

Posted 1/17/2024 (updated 3/29/2024)

This webinar aims to provide a comprehensive review of the latest updates in DATA Waiver and DEA Training prerequisites for medication-assisted treatment (MAT) and buprenorphine. It will explore the reasons behind the implementation of the Waiver Elimination (MAT-Act), outline the key components of the MAT-Act that took effect in 2023, highlight the advantages of the MAT-Act for healthcare providers and prescribers, and inform participants about the free training and consultation opportunities related to the treatment of patients with Opioid Use Disorder (MOUD).